States probe Eli Lilly over insulin prices

礼来公司胰岛素产品被指定价过高,遭美国多个州司法部门调查

2019-08-06 16:06:00 pharmamanufacturing

本文共368个字,阅读需1分钟

Eli Lilly has been hit with a subpoena from the New York Attorney General’s Office over the pricing and sales of its insulin treatments. The drugmaker disclosed the probe a recent filing with the Securities and Exchange Commission. According to Lilly, attorney general offices in Mississippi, Washington D.C., California, Florida, Hawaii, and Nevada are also seeking information on its pricing, Lilly's blockbuster insulin, Humalog, brings in $3 billion in annual sales. In March, the drugmaker announced its plan to sell an authorized generic version, called n Lispro, for half the cost. The pricing probe has been ongoing for Lilly. Early this year, members of Congress sent letters to Eli Lilly, Novo Nordisk and Sanofi inquiring about rising insulin prices. The letters requested information from the drugmakers on pricing and the obstacles to providing more affordable insulin, by February 13, 2019.
礼来( Eli Lilly )因其胰岛素治疗产品的定价和销售受到了纽约总检察长办公室的传票的打击。 这家制药商最近向美国证券交易委员会( SEC )披露了这一调查。据礼来(Lilly)说,密西西比州、华盛顿特区、加利福尼亚州、弗洛里达州、夏威夷和内华达州的总检察长办公室也在寻求有关其定价的信息。 礼来(Lilly)的重磅炸弹胰岛素 Humalog 每年带来30亿美元的销售额。今年3月,这家制药商宣布计划以一半的成本销售授权仿制药,名为 nLispro 。 礼来(Lilly)公司正在进行定价调查。今年早些时候,国会议员写信给礼来(Eli Lilly)、诺和诺德(Novo Nordisk)和赛诺菲(Sanofi),询问胰岛素价格的上涨。这些信件要求制药商在2019年2月13日之前提供有关定价和提供更多负担得起的胰岛素的障碍的信息。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文